Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

COX-2 expression associated with H Pylori and gastric cancer

The latest Journal of Clinical Gastroenterology shows that H pylori is associated with the colonic-phenotype of gastric intestinal metaplasia, and COX-2 reactivity in the gastric intestinal metaplasia identifies those at risk for cancer.

News image

fiogf49gjkf04

Gastric intestinal metaplasia associated with Helicobacter pylori has been considered a premalignant lesion.

However, gastric intestinal metaplasia phenotype associated with H pylori infection and gastric cancer is unclear.

The expression of cyclooxygenase-2 (COX-2) in relation to gastric intestinal metaplasia phenotype is also unknown.

Dr John Sun and colleagues from Japan evaluated cellular phenotype and cyclooxygenase-2 expression in gastric intestinal metaplasia.

The research team assessed 31 H pylori-positive and -negative patients in the absence of gastric cancer.

The team used a colon epithelium specific monoclonal antibody (mAb Das-1) and anti-cyclooxygenase-2 antibody.

COX-2 expression was found in 32% with H pylori-positive gastric intestinal metaplasia
Journal of Clinical Gastroenterology

Cyclooxygenase-2 expression was also examined in 34 patients with gastric cancer.

The team examined both the cancer and in the gastric intestinal metaplasia areas away from the cancer field.

The researchers found that 68% of H pylori-positive gastric intestinal metaplasia reacted with mAb Das-1.

However, the reactivity in the H pylori -negative gastric intestinal metaplasia was only 25%.

The team noted that cyclooxygenase-2 expression was present in 32% of H pylori-positive gastric intestinal metaplasia patients.

Cyclooxygenase-2 expression was present in only 9% of H pylori-negative gastric intestinal metaplasia patients.

In the cancer group, cycooxegenase-2 expression was localized in 94% of the cancer area and in 82% with gastric intestinal metaplasia away from the cancer.

The team observed that each of the cyclooxygenase-2-positive tissue was also positive to the monoclonal antibody, mAb Das-1.

Dr Sun's team concluded, “H pylori infection is highly associated with the development of colonic-phenotype of gastric intestinal metaplasia.”

“About half of them expressed cyclooxygenase-2.”

“Cyclooxygenase-2 expression was frequent in both gastric cancer and the gastric intestinal metaplasia adjacent to the cancer.”

“The results suggest that the presence of mAb Das-1 and cyclooxygenase-2 reactivity in the gastric intestinal metaplasia identify the subgroup of patients who may be at risk for gastric cancer and may need close surveillance.”

J Clin Gastroenterol 2006: 40(2): 122-8
27 February 2006

Go to top of page Email this page Email this page to a colleague

 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us